Relay Therapeutics, Inc.
Clinical trials sponsored by Relay Therapeutics, Inc., explained in plain language.
A precision medicine company developing targeted cancer therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for hard-to-treat breast cancer: targeted combo enters late-stage trial
Disease control Recruiting nowThis study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New targeted drug hopes to shrink NRAS-Driven cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants…
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC